Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1364764 | Bioorganic & Medicinal Chemistry Letters | 2008 | 6 Pages |
Abstract
An imidazole series of cyclin-dependent kinase (CDK) inhibitors has been developed. Protein inhibitor structure determination has provided an understanding of the emerging structure activity trends for the imidazole series. The introduction of a methyl sulfone at the aniline terminus led to a more orally bioavailable CDK inhibitor that was progressed into clinical development.
Graphical abstractThe SAR and development of an imidazole series (3) of CDK inhibitors are reported.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Malcolm Anderson, David M. Andrews, Andy J. Barker, Claire A. Brassington, Jason Breed, Kate F. Byth, Janet D. Culshaw, M. Raymond V. Finlay, Eric Fisher, Helen H.J. McMiken, Clive P. Green, Dave W. Heaton, Ian A. Nash, Nicholas J. Newcombe,